Anxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice

Hormones and Behavior

Volumn 60, Issue 3, 2011, Pages 292-300

  Miguel, Tarciso Tadeu ^a,b   Nunes de Souza, Ricardo Luiz ^a,b  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Antinociception; Anxiety; CRF1 and CRF2 receptors; Elevated plus maze; Mice; Periaqueductal gray

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTISAUVAGINE 30; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MALE; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL;

ANALGESICS; ANILINE COMPOUNDS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; MALE; MICE; PAIN; PEPTIDE FRAGMENTS; PERIAQUEDUCTAL GRAY; PYRIMIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 79960562237     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2011.06.004     Document Type: Article

References (72)

1. Abbott F.V., Franklin K.B., Westbrook R.F. The formalin test: scoring properties of the first and the second phases of the pain response in rats. Pain 1995, 60(1):91-102.
2. Allen C.D., Lee S., Koob G.F., Rivier C. Immediate and prolonged effects of alcohol exposure on the activity of the hypothalamic-pituitary-adrenal axis in adults and adolescent rats. Brain Behav. Immun. 2011, 25(1):S50-S60.
3. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the anxiogenic response to ethanol withdrawal in the rat. Psychopharmacology 1991, 103(2):227-232.
4. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 2000, 24(4):410-414.
5. Bandler R., Carrive P. Integrated defense reaction elicited by excitatory amino acid in the midbrain periaquedutal gray region of the unrestrained cat. Brain Res. 1988, 439(1-2):95-106.
6. Bandler R., Carrive P., Zhang S.P. Integration of somatic and autonomic reactions within the midbrain periaqueductal grey: viscerotopic, somatotopic and functional organization. Prog. Brain Res. 1991, 87:267-305.
7. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog. Neurobiol. 1995, 46:575-605.
8. Berridge C.W., Dunn A.J. CRF and restraint stress decrease exploratory behavior hypophisectomized mice. Pharmacol. Biochem. Behav. 1989, 34(3):517-519.
9. Bogdanov A.I., Yarushkina N.I. The role of hormones of the hypothalamo-hypophyseal-adrenocortical system in the analgesic effect of corticotropin-releasing hormone. Neurosci. Behav. Physiol. 2007, 37(4):363-367.
10. Bolles R.C., Fanselow M.S. A perceptual-defensive-recuperative model of fear and pain. Behav. Brain Sci. 1980, 3:291-322.
11. Bon K., Wilson S.G., Mogil J.S., Roberts W.J. Genetic evidence for the correlation of deep dorsal horn Fos protein immunoreactivity with tonic formalin pain behavior. J. Pain 2002, 3(3):181-189.
12. Borelli K.G., Brandão M.L. Effects of ovine CRF injections into the dorsomedial, dorsolateral and lateral columns of the periaqueductal gray: a functional role for the dorsomedial column. Horm. Behav. 2008, 53(1):40-50.
13. Bowers L.K., Swisher C.B., Behbehani M.M. Membrane and synaptic effects of corticotropin-releasing factor on periaqueductal gray neurons of the rat. Brain Res. 2003, 981:52-57.
14. Carrasco G.A., Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 2003, 463:235-272.
15. Carvalho-Netto E.F., Litvin Y., Nunes-de-Souza R.L., Blanchard D.C., Blanchard R.J. Effects of intra-PAG infusions of ovine CRF on defensive behaviors in Swiss-Webster mice. Behav. Brain Res. 2007, 176(2):222-229.
16. Casada J.H., Dafny N. Restraint and stimulation of bed nucleus of the stria terminalis produce similar stress-like behavior. Brain Res. Bull. 1991, 27(2):207-212.
17. Chang C.P., Pearse R.V., O'Connel S., Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993, 11:1187-1195.
18. Chen M.F., Chiu T.H., Lee E.H. Noradrenergic mediation of the memory-enhancing effect of corticotropin-releasing factor in the locus coeruleus of rats. Psychoneuroendrocrinology 1992, 17(2-3):113-124.
19. Chen R., Lewis K.A., Perrin M.W., Vale W.W. Expression cloning of a human corticotropin-releasing factor receptor. Proc. Natl. Acad. Sci. U S A 1993, 90:8967-8971.
20. Chen W., Shields J., Huang H., King J.A. Female fear: influence of estrus cycle on behavioral response and neuronal activation. Behav. Brain Res. 2009, 201(1):8-13.
21. Coimbra N.C., Brandão M.L. Effects of 5-HT2 receptors blockade on fear-induced analgesia elicited by electrical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray. Behav. Brain Res. 1997, 87(1):97-103.
22. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., Gold L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 1999, 835(1):1-9.
23. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus maze. Pharmacol. Biochem. Behav. 1994, 49(1):171-176.
24. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defense. Psychopharmacology 1991, 5:305-315.
25. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stimulation in rats and cats. Pain 1977, 4:161-174.
26. Fanselow M.S. The midbrain periaqueductal gray as a coordinator of action in response to fear and anxiety. The Midbrain Periaqueductal Gray Matter 1991, 151-173. Plenum Press, New York. A. Depaulis, R. Bandler (Eds.).
27. Fardin V., Oliveras J.L., Besson J.M. A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat I. The production of behavioral side effects together with analgesia. Brain Res. 1984, 306(1-2):105-123.
28. Fardin V., Oliveras J.L., Besson J.M. A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat II. Diferential characteristics of the analgesia induced by ventral and dorsal PAG stimulation. Brain Res. 1984, 306(1-2):125-139.
29. Fields H.L., Basbaum A.I. Central nervous system mechanisms of pain modulation. Textbook of Pain 1999, 206-217. Churchill Livingstone, New York. P.D. Wall, R. Melzack (Eds.).
30. Gray T.S., Magnuson D.J. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides 1992, 13(3):451-460.
31. Hammack S.E., Schmid M.J., LoPresti M.L., Der-Avakian A., Pellymounter L.A., Forster A.C., Watkins L.R., Maier S.F. Corticotropin-releasing hormone type 2 receptor in the dorsal raphé nucleus mediate the behavioral consequence of incontrolable stress. J. Neurosci. 2003, 23(3):1019-1025.
32. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonist and antagonist in a maze-exploration model of fear-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 1984, 327(1):1-5.
33. Harris J.A. Descending antinociceptive mechanisms in the brainstem: their role in the animal's defensive system. J. Physiol. 1996, 90:15-25.
34. Hayward L.F., Schwartz C.L., Davenport P.W. Respiratory response to activation or disinhibition of the dorsal periaqueductal gray in rats. J. Appl. Physiol. 2003, 94(3):913-922.
35. Jochman K.A., Newman S.M., Kalin N.H., Bakshi V.P. Corticotropin-releasing factor-1 receptors in the basolateral amygdala mediate stress-induced anorexia. Behav. Neurosci. 2005, 119(6):1448-1458.
36. Kanner A.M. Depression and epilepsy: a bidirectional relation?. Epilepsia 2011, 52:21-27.
37. Kharkevich D.A., Churukanov V.V. Pharmacological regulation of descending cortical control of the nociceptive processing. Eur. J. Pharmacol. 1999, 375(1-3):121-131.
38. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., Hermanson O., Rosenfeld M.G., Spiess J. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat. Genet. 2000, 24:415-419.
39. Lariviere W.R., Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain 2000, 84(1):1-12.
40. Lim L.W., Blockland A., van Duinem M., Visser-Vanderwalle V., Tan S., Vlamings L., Janssen M., Jahanshahi A., Aziz-Mohammadi M., Steinbusch H.W.M., Schruers K., Temel Y. Increased plasma corticotestorone levels after periaqueductal gray stimulation-induced escape reaction or panic attacks in rats. Behav. Brain Res. 2011, 218:301-307.
41. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
42. Litvin Y., Pentkowiski N.S., Blanchard D.C., Blanchard R.J. CRF type 1 receptors in the dorsal periaqueductal gray modulate anxiety-induced defensive behaviors. Horm. Behav. 2007, 52(2):244-251.
43. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U S A 1995, 92:836-840.
44. Martins A.P., Marras R.A., Guimarães F.S. Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal gray. Neuroreport 1997, 8:3601-3604.
45. Martins A.P., Marras R.A., Guimarães F.S. Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray. Depress. Anxiety 2000, 12:99-101.
46. McCall W.D., Tanner K.D., Levine J.D. Formalin induces biphasic activity in C-fibers in the rat. Neurosci. Lett. 1996, 208(1):41-48.
47. McDougall A., Dampney R., Bandler R. Cardiovascular components of the defence reaction evoked by excitation of neuronal cell bodies in the midbrain periaqueductal grey of the cat. Neurosci. Lett. 1985, 60(1):69-75.
48. Merchenthaler I. Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 1984, 5:53-69.
49. Millan M.J. Descending control of pain. Prog. Neurobiol. 2002, 66:355-474.
50. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31(9):464-468.
51. The mouse brain in stereotaxic coordinates 2001, Academic Press, California, USA. G. Paxinos, K.B.J. Franklin (Eds.).
52. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
53. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U S A 1995, 92:2969-2973.
54. Radulovic J., Ruhmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J. Neurosci. 1999, 19(12):5016-5025.
55. Risbrough V.B., Haugher L.R., Pelleymounter M.A., Geyer M.A. Role of corticotropin-releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology 2003, 170:178-187.
56. Rodgers R.J. Neuropharmacological aspects of adaptative pain inhibition in murine victims of aggression. Aggress. Behav. 1995, 21:29-39.
57. Rodgers J.R., Johnson N.J. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 1995, 52(2):297-303.
58. Sahuque L.L., Kullberg E.F., Mcgeehan A.J., Kinder J.R., Hicks M.P., Blanton M.G., Janak P.H., Olive M.F. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology (Berl) 2006, 186(1):122-132.
59. Schenberg L.C., Póvoa R.M., Costa A.L., Caldellas A.V., Tufik S., Bittencourt A.S.L. Functional specializations within the tectum defense systems of the rat. Neurosci. Biobehav. Rev. 2005, 29:1279-1298.
60. Shekhar A., Truitt W., Rainnie D., Sajdyk T. Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 2005, 8(4):209-219.
61. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998, 20:1093-1102.
62. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol. Psychiatry 1999, 46:1480-1508.
63. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotopin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 1994, 14:2579-2584.
64. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983, 36:165-186.
65. Takahashi L.K., Ho S.P., Livanov V., Graciani N., Arneric S.P. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 2001, 902:135-142.
66. Tezval H., Jahn O., Todorovic C., Sasse A., Eckart K., Spiess J. Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse models. Proc. Natl. Acad. Sci. U S A 2004, 101(25):9468-9473.
67. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 1998, 19:162-166.
68. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 1993, 44:463-469.
69. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., Rivier J., Sawchenko P.E., Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin releasing factor. Nature 1995, 378:287-292.
70. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M., Le Fur G., Caput D., Ferrara P. Primary structure and functional expression of mouse pituitary and human brain corticotropin-releasing factor receptor. FEBS Lett. 1993, 335:1-5.
71. Walker D.L., Toufexis D.J., Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress and anxiety. Eur. J. Pharmacol. 2003, 463:199-216.
72. Zhao Y., Valdez G.R., Fekete E.M., Rivier J.E., Vale W.W., Rice K.C., Weiss F., Zorrilla E.P. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J. Pharmacol. Exp. Ther. 2007, 323(3):846-854.